Latest Breaking News On - International oncolytic virus conference - Page 1 : vimarsana.com

Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K -March 28, 2024 at 07:48 am EDT

Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for.

Aljanae reynoldsTheodore jenkinsCandel therapeutics incExchange commissionDevelopment expensesDrug administrationBusiness developmentSociety for immunotherapy of cancerDevelopment service revenueInternational oncolytic virus conferenceCompany nasdaqCandel therapeutics reports fourth quarterFull yearRecent corporate highlightsTrack designationsTrack designation

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in.

Aljanae reynoldsTheodore jenkinsDevelopment expensesDevelopment service revenueExchange commissionCompany nasdaqCandel therapeutics incInternational oncolytic virus conferenceSociety for immunotherapy of cancerBusiness developmentDrug administrationTrack designationsTrack designationPaul peter takFast track designationHigh grade glioma

Candel Therapeutics (CADL) Announces Restructuring to Prioritize Resources on Key Value Drivers

Candel Therapeutics (CADL) Announces Restructuring to Prioritize Resources on Key Value Drivers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Candel therapeutics incUniversity of pennsylvania centerDuring the society for immunotherapy of cancerCompany nasdaqCandel therapeuticsDiscovery platformPaul peter takPennsylvania centerInternational oncolytic virus conferenceBreak through cancer

Theolytics presents CAF-targeting therapy for stromal rich tumours, and strengthens leadership team as pipeline accelerates into the clinic

/PRNewswire/ Theolytics, a biotechnology company harnessing viruses to combat disease, will release data on their proprietary systemic therapy for.

United statesUnited kingdomMargaret duffyPrnewswire theolyticsCharlotte casebourneVectura groupInternational oncolytic virus conferenceSosei group corpTranslational developmentOncolytic virus conferenceChief scientific officerAndrew oakleyChief financial officerMiriam bazan peregrinoVice president translationalChief executive officer

Denovo Biopharma LLC Announces Multiple Presentations at Major Conferences

/PRNewswire/ Denovo Biopharma LLC (Denovo), a pioneer in using biomarker-guided precision medicine to develop innovative therapies, today announced.

United statesMichaelf hallerDenovo biopharmaEli lillyPrnewswire denovo biopharmaInternational oncolytic virus conferenceSociety for neurooncologyEli lilly coAlbany molecular research incAnnual meetingPharmacogenomic biomarkerFailed clinical trialExceptional responderEnzastaurin long term efficacyRecurrent glioblastoma multiformeFast track designation